Dan T. Vogl
0000-0002-2935-2566
Publication & Citation Trends
Publications
0 total
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy
Cited by 0
Semantic Scholar
The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target
Cited by 0
Semantic Scholar
Outcomes of Radiation Therapy Integrated with T-cell Engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Cited by 0
Semantic Scholar
Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Preliminary Safety and Efficacy Data from the “STEM” (Sequential T Cell-Engagement for Myeloma) Trial
Cited by 0
Semantic Scholar
Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
Cited by 2
Semantic Scholar
A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma.
Cited by 0
Semantic Scholar
Consolidative Use of BCMA CAR-T Therapy in Relapsed/Refractory Myeloma — A Retrospective Evaluation
Cited by 0
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(193)
CAR-T cell therapy research
(70)
Protein Degradation and Inhibitors
(51)
Immunotherapy and Immune Responses
(37)
Cancer Treatment and Pharmacology
(37)
Affiliations
University of Maryland, Baltimore
American Cancer Society
United Cerebral Palsy
Memorial Sloan Kettering Cancer Center
Johns Hopkins University